Author:
Xu Jin-fu,Gao Yong-hua,Song Yuan-lin,Qu Jie-ming,Guan Wei-jie
Abstract
Bronchiectasis is a debilitating chronic suppurative airway disease that confers a substantial burden globally. Despite the notable prevalence, research on bronchiectasis in mainland China remains in its infancy. Nevertheless, there has been a significant leap in the quantity and quality of research, which has contributed to the ever-improving clinical practice. A nationwide collaborative platform has been established to foster multicentre studies, which will help increase the level of evidence further. Here, we summarise the status quo of clinical management and consider the research priorities for bronchiectasis that have been published previously. We also highlight the efforts of the Chinese medical communities to outline the core tasks that need to be addressed within the next decade.
Funder
National Natural Science Foundation of China
Zhongnanshan Medical Foundation of Guangdong Province
Shanghai Pujiang Program 2021
Publisher
European Respiratory Society (ERS)
Subject
Pulmonary and Respiratory Medicine
Reference83 articles.
1. British Thoracic Society Guideline for bronchiectasis in adults
2. [The prevalence and risk factors of bronchiectasis in residents aged 40 years old and above in seven cities in China];Zhou;Zhonghua Nei Ke Za Zhi,2013
3. Sputum Elastase in Steady-State Bronchiectasis
4. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis;Tsang;Am J Respir Crit Care Med,1998
5. Bronchiectasis in China;Lin;Ann Am Thorac Soc,2016